Serum Institute of India managing director Dr Cyrus S Poonawalla, who was awarded the Padma Bhushan on Tuesday, said it was a great privile...

Bharat Biotech's Covaxin is credited to be India's first indigenous COVID-19 vaccine to be approved and administered to a sizeable populati...

Terming the achievement as a "true success story of Atmanirbharta", he said that it was a unified effort of the government, vaccine manufac...

Karnataka has so far conducted 1.12 crore inoculations of coronavirus vaccines in the state comprising first and second doses whereas it ha...

Krishna Ella, whose firm developed India's first indigenous vaccine for Covid-19, said 'pandemic vaccines and everything in future will com...

I humbly appeal to everyone, not as a Health Minister but as a fellow medical professional, to refrain from unwarranted criticism which dis...

Covaxin, being developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, was...

Hyderabad-based Bharat Biotech said on Monday that its vaccine is efficient against the mutant strain of novel coronavirus found in the UK ...

The approval of Covaxin for emergency use is a giant leap for innovation and novel product development in India, Krishna Ella, Chairman and...

Bharat Biotech has got nod from the DCGI to begin human trials of the first indigenous Covid-19 vaccine.

The SARS-CoV-2 strain was isolated in NIV and transferred to Bharat Biotech, which has developed the indigenous, inactivated vaccine at its...

Buy Granules India Ltd. at a price target of Rs 116.0 and a stop loss at Rs 107.5 from the entry point.

Buy Granules India Ltd. at a price target of Rs 140.0 and a stop loss at Rs 128 from entry point.

Bharat Biotech’s chief managing director Dr Krishna Ella said his company has ‘an early mover advantage’ in developing the Zika vaccine.

Investment banker Avendus has been mandated by ICICI Ventures to find suitors and the initial process has begun, sources in the know said.

India annually suffers a staggering revenue loss of about Rs 20,000 crore due to Foot and Mouth Disease that afflicts the bovine population...

Biovet has launched Asia's first Bio Safety Level-4 (BSL-4) manufacturing facility, specifically designed to enable product development and...